论文部分内容阅读
在恶性肿瘤的治疗中,肠毒素C2(SEC2)的临床应用由于其副作用而被严重限制。利用SEC2基因截短技术,获得保留T细胞刺激活力又不引发催吐效应的SEC2突变株,可有效解决这个问题。根据噻唑蓝比色法(MTT)分析结果,新型截短肠毒素C2突变株(NSM)可显著刺激T细胞增殖,并且可显著抑制人大肠癌细胞(CX-1)和人乳腺癌细胞(MCF-7)生长。NSM的T细胞刺激能力和抑瘤效果与SEC2相似。动物研究结果证明NSM不再引发呕吐效应,且可显著抑制荷瘤小鼠的肿瘤生长。因此,这种可抑制肿瘤细胞生长的新型截短肠毒素C2突变株有可能成为无副作用的新型抗肿瘤生物制剂。
In the treatment of malignant tumors, the clinical application of enterotoxin C2 (SEC2) is severely limited due to its side effects. The use of SEC2 gene truncation technology to obtain retain T cell stimulating activity without inducing the emetic effect of SEC2 mutant can be an effective solution to this problem. According to the results of MTT assay, the new type of enterotoxigenic C2 mutant (NSM) significantly stimulated the proliferation of T cells and inhibited the proliferation of human colon cancer cells (CXC-1) and human breast cancer cells (MCFs) -7) growth. T cell stimulation of NSM and anti-tumor effect and SEC2 similar. Animal studies show that NSM no longer elicits vomiting effects and can significantly inhibit tumor growth in tumor-bearing mice. Therefore, this new type of recombinant enterotoxin C2 mutant that inhibits the growth of tumor cells may become a novel antitumor biological agent without side effects.